Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus target price of $35.67 for the company and are predicting that the company will post ($0.74) EPS for the current quarter, according to Zacks. Zacks has also assigned Kiniksa Pharmaceuticals an industry rank of 58 out of 256 based on the ratings given to related companies.
A number of research analysts have issued reports on KNSA shares. Zacks Investment Research cut Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective (up from $31.00) on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, December 12th. Finally, JMP Securities boosted their target price on Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the company an “outperform” rating in a research note on Monday, September 17th.
KNSA stock traded down $0.41 during midday trading on Wednesday, hitting $21.75. The company’s stock had a trading volume of 5,004 shares, compared to its average volume of 90,775. Kiniksa Pharmaceuticals has a 52-week low of $13.04 and a 52-week high of $32.88.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Thursday, November 1st. The company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.03. As a group, equities analysts forecast that Kiniksa Pharmaceuticals will post -2.63 EPS for the current fiscal year.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Story: What is a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.